These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38293023)

  • 21. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
    Ho CY; Mealiffe ME; Bach RG; Bhattacharya M; Choudhury L; Edelberg JM; Hegde SM; Jacoby D; Lakdawala NK; Lester SJ; Ma Y; Marian AJ; Nagueh SF; Owens A; Rader F; Saberi S; Sehnert AJ; Sherrid MV; Solomon SD; Wang A; Wever-Pinzon O; Wong TC; Heitner SB
    J Am Coll Cardiol; 2020 Jun; 75(21):2649-2660. PubMed ID: 32466879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Septal Reduction Therapy on Acute Cardiovascular Events and All-Cause Mortality in Patients with Hypertrophic Cardiomyopathy.
    Morita SX; Zhao Y; Hasegawa K; Fifer MA; Maurer MS; Reilly MP; Takayama H; Shimada YJ
    Int Heart J; 2021 Sep; 62(5):1035-1041. PubMed ID: 34544977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Saliency maps provide insights into artificial intelligence-based electrocardiography models for detecting hypertrophic cardiomyopathy.
    Siontis KC; Suárez AB; Sehrawat O; Ackerman MJ; Attia ZI; Friedman PA; Noseworthy PA; Maanja M
    J Electrocardiol; 2023; 81():286-291. PubMed ID: 37599145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Spertus JA; Fine JT; Elliott P; Ho CY; Olivotto I; Saberi S; Li W; Dolan C; Reaney M; Sehnert AJ; Jacoby D
    Lancet; 2021 Jun; 397(10293):2467-2475. PubMed ID: 34004177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.
    Xie J; Wang Y; Xu Y; Fine JT; Lam J; Garrison LP
    J Med Econ; 2022; 25(1):51-58. PubMed ID: 34907813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Large Q and S waves in lead III on the electrocardiogram distinguish patients with hypertrophic cardiomyopathy from athletes.
    Chen AS; Bent RE; Wheeler M; Knowles JW; Haddad F; Froelicher V; Ashley E; Perez MV
    Heart; 2018 Nov; 104(22):1871-1877. PubMed ID: 29680808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
    Wheeler MT; Jacoby D; Elliott PM; Saberi S; Hegde SM; Lakdawala NK; Myers J; Sehnert AJ; Edelberg JM; Li W; Olivotto I
    Eur J Heart Fail; 2023 Feb; 25(2):260-270. PubMed ID: 36404399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
    Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy.
    Tower-Rader A; Ramchand J; Nissen SE; Desai MY
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomechanical response of ultrathin slices of hypertrophic cardiomyopathy tissue to myosin modulator mavacamten.
    Amesz JH; Langmuur SJJ; Zhang L; Manintveld OC; Schinkel AFL; de Jong PL; de Groot NMS; Taverne YJHJ
    Biomed Pharmacother; 2024 Jan; 170():116036. PubMed ID: 38134635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy.
    Pysz P; Rajtar-Salwa R; Smolka G; Olivotto I; Wojakowski W; Petkow-Dimitrow P
    Kardiol Pol; 2021; 79(9):949-954. PubMed ID: 34268723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca
    Sparrow AJ; Watkins H; Daniels MJ; Redwood C; Robinson P
    Am J Physiol Heart Circ Physiol; 2020 Mar; 318(3):H715-H722. PubMed ID: 32083971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials.
    Rabiee Rad M; Ghasempour Dabaghi G; Habibi D
    Egypt Heart J; 2023 Jan; 75(1):4. PubMed ID: 36633717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
    Hegde SM; Lester SJ; Solomon SD; Michels M; Elliott PM; Nagueh SF; Choudhury L; Zemanek D; Zwas DR; Jacoby D; Wang A; Ho CY; Li W; Sehnert AJ; Olivotto I; Abraham TP
    J Am Coll Cardiol; 2021 Dec; 78(25):2518-2532. PubMed ID: 34915982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying Obstructive Hypertrophic Cardiomyopathy from Nonobstructive Hypertrophic Cardiomyopathy: Development and Validation of a Model Based on Electrocardiogram Features.
    Guo L; Ma Z; Yang W; Zhang F; Shao H; Liu L; Gao C; Tao L
    Glob Heart; 2023; 18(1):40. PubMed ID: 37547171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.
    Bertero E; Chiti C; Schiavo MA; Tini G; Costa P; Todiere G; Mabritto B; Dei LL; Giannattasio A; Mariani D; Lofiego C; Santolamazza C; Monda E; Quarta G; Barbisan D; Mandoli GE; Mapelli M; Sguazzotti M; Negri F; De Vecchi S; Ciabatti M; Tomasoni D; Mazzanti A; Marzo F; de Gregorio C; Raineri C; Vianello PF; Marchi A; Biagioni G; Insinna E; Parisi V; Ditaranto R; Barison A; Giammarresi A; De Ferrari GM; Priori S; Metra M; Pieroni M; Patti G; Imazio M; Perugini E; Agostoni P; Cameli M; Merlo M; Sinagra G; Senni M; Limongelli G; Ammirati E; Vagnarelli F; Crotti L; Badano L; Calore C; Gabrielli D; Re F; Musumeci G; Emdin M; Barbato E; Musumeci B; Autore C; Biagini E; Porto I; Olivotto I; Canepa M
    Eur J Heart Fail; 2024 Jan; 26(1):59-64. PubMed ID: 38131253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions.
    Dong T; Alencherry B; Ospina S; Desai MY
    Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy.
    Desai MY; Hajj Ali A
    Heart Int; 2023; 17(1):2-4. PubMed ID: 37456351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multinational Federated Learning Approach to Train ECG and Echocardiogram Models for Hypertrophic Cardiomyopathy Detection.
    Goto S; Solanki D; John JE; Yagi R; Homilius M; Ichihara G; Katsumata Y; Gaggin HK; Itabashi Y; MacRae CA; Deo RC
    Circulation; 2022 Sep; 146(10):755-769. PubMed ID: 35916132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy.
    Scholtz S; Rudolph V; Reil JC
    J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.